MedTrace Logo

Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) in Migraine Prophylaxis

NCT03190044 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2018-12-11

No results posted yet for this study

Summary

Migraine is a highly disabling disorder that affects hundreds of millions of people around the world. Yet, a little number of prophylactic treatments are available still now. The limited number of available drugs leads to a wide use of nutraceutical compounds in migraine therapy. To improve the efficacy, some of these nutraceuticals were combined. So far, we do not know if these combinations are really more effective than the single compounds alone, or an anti-synergic effect could be present because of a reciprocal antagonism of effects. For this reason, we decided to test the efficacy of a fixed combination of magnesium, partenium, andrographis, co-enzyme Q10 and riboflavin (PACR) as prophylactic treatment for migraine in a randomized controlled double blind study.

Conditions

  • Migraine Disorders

Interventions

DIETARY_SUPPLEMENT

PACR

Daily assumption of PACR for a 3-month period

DIETARY_SUPPLEMENT

Placebo

Daily assumption of placebo

Sponsors & Collaborators

  • Gianluca Coppola

    collaborator UNKNOWN

  • Francesco Pierelli

    collaborator UNKNOWN

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Francesco Pierelli, MD · University of Roma La Sapienza

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-06
Primary Completion
2019-12-30
Completion
2019-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03190044 on ClinicalTrials.gov